Published in Int J Chron Obstruct Pulmon Dis on February 14, 2012
A review of national guidelines for management of COPD in Europe. Eur Respir J (2016) 0.99
Continuing to Confront COPD International Physician Survey: physician knowledge and application of COPD management guidelines in 12 countries. Int J Chron Obstruct Pulmon Dis (2014) 0.96
Continuing to confront COPD International Surveys: comparison of patient and physician perceptions about COPD risk and management. Int J Chron Obstruct Pulmon Dis (2015) 0.88
Real-life GOLD 2011 implementation: the management of COPD lacks correct classification and adequate treatment. PLoS One (2014) 0.85
Low intensity, long-term outpatient rehabilitation in COPD: a randomised controlled trial. Respir Res (2012) 0.85
Atorvastatin improves endothelial progenitor cell function and reduces pulmonary hypertension in patients with chronic pulmonary heart disease. Exp Clin Cardiol (2013) 0.79
Evaluation of the Persian Transcript of the COPD Assessment Test in the Measurement of COPD Health Status in Iranian COPD Patients. Glob J Health Sci (2015) 0.75
Characterization of secondary care for COPD in Sweden. Eur Clin Respir J (2017) 0.75
Validity and Usability of Physical Activity Monitoring in Patients with Chronic Obstructive Pulmonary Disease (COPD). PLoS One (2016) 0.75
Factors facilitating and hindering the intention to promote pulmonary rehabilitation for patients with COPD among respiratory therapists. Int J Chron Obstruct Pulmon Dis (2017) 0.75
Interpretative strategies for lung function tests. Eur Respir J (2005) 21.50
Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J (2004) 16.84
The global burden of disease, 1990-2020. Nat Med (1998) 6.50
Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J (2006) 3.89
Extrapulmonary effects of chronic obstructive pulmonary disease on physical activity: a cross-sectional study. Am J Respir Crit Care Med (2007) 2.93
Knowledge, patterns of care, and outcomes of care for generalists and specialists. J Gen Intern Med (1999) 2.76
Pulmonary rehabilitation for management of chronic obstructive pulmonary disease. N Engl J Med (2009) 2.21
Practice patterns in the management of chronic obstructive pulmonary disease in primary practice: the CAGE study. Can Respir J (2008) 1.80
Outpatient pulmonary rehabilitation following acute exacerbations of COPD. Thorax (2010) 1.79
Are patients with COPD more active after pulmonary rehabilitation? Chest (2008) 1.69
Respiratory rehabilitation after acute exacerbation of COPD may reduce risk for readmission and mortality -- a systematic review. Respir Res (2005) 1.51
Outcome measures in chronic obstructive pulmonary disease (COPD): strengths and limitations. Respir Res (2010) 1.31
[Guidelines for the diagnosis and therapy of COPD issued by Deutsche Atemwegsliga and Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin]. Pneumologie (2007) 1.23
Knowledge of guidelines for the management of COPD: a survey of primary care physicians. Respir Med (2004) 1.22
National survey of guideline-compliant COPD management among pneumologists and primary care physicians. COPD (2006) 1.17
Do family physicians' records fit guideline diagnosed COPD? Fam Pract (2009) 1.02
Quality of COPD care in hospital outpatient clinics in Denmark: The KOLIBRI study. Respir Med (2009) 1.01
Differences in COPD care among doctors who control the disease: general practitioner vs. pneumologist. Respir Med (2005) 0.90
[Guidelines for the diagnosis and treatment chronic obstructive bronchitis and pulmonary emphysema issued by Deutsche Atemwegsliga and Deutsche Gesellschaft für pneumologie]. Pneumologie (2002) 0.90
COPD health care in Sweden - A study in primary and secondary care. Respir Med (2009) 0.89
Epidemiology and health economics of COPD across Europe: a critical analysis. Treat Respir Med (2005) 0.87
Changes in management of chronic obstructive pulmonary disease (COPD) in primary care: EMMEPOC study. Respir Med (2010) 0.82
Pulmonary rehabilitation as evaluated by clinical trials: an overview. Rev Recent Clin Trials (2010) 0.81
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med (2012) 22.96
High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med (2005) 7.20
Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet (2012) 5.82
Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2006) 4.82
An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest (2003) 3.19
FAQs about the GOLD 2011 assessment proposal of COPD: a comparative analysis of four different cohorts. Eur Respir J (2013) 2.87
Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax (2010) 2.79
Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme. N Engl J Med (2015) 2.44
Neutrophil chemotactic activity of sputum from patients with COPD: role of interleukin 8 and leukotriene B4. Chest (2003) 2.04
Patient understanding, detection, and experience of COPD exacerbations: an observational, interview-based study. Chest (2006) 1.84
An Official American Thoracic Society/European Respiratory Society Statement: Research questions in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2015) 1.63
New horizons in early stage COPD--improving knowledge, detection and treatment. Respir Med (2011) 1.56
Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer--what limits limited disease? Lung Cancer (2002) 1.53
Effectiveness of omalizumab in patients 50 years and older with severe persistent allergic asthma. Ann Allergy Asthma Immunol (2010) 1.47
Comparison of two devices and two breathing patterns for exhaled breath condensate sampling. PLoS One (2011) 1.45
Overall asthma control: the relationship between current control and future risk. J Allergy Clin Immunol (2010) 1.41
QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease. Thorax (2010) 1.36
Lung function in idiopathic pulmonary fibrosis--extended analyses of the IFIGENIA trial. Respir Res (2009) 1.34
Lung Transplantation in Germany Since the Introduction of the Lung Allocation Score. Dtsch Arztebl Int (2017) 1.34
TNF-alpha, TNF-beta, IL-6, and IL-10 polymorphisms in patients with lung cancer. Dis Markers (2005) 1.32
Allergic airway inflammation inhibits pulmonary antibacterial host defense. J Immunol (2006) 1.31
Outcome measures in chronic obstructive pulmonary disease (COPD): strengths and limitations. Respir Res (2010) 1.31
The discovery of α1-antitrypsin and its role in health and disease. Respir Med (2011) 1.30
Specific IgE against Staphylococcus aureus enterotoxins: an independent risk factor for asthma. J Allergy Clin Immunol (2012) 1.28
Peripheral arterial tonometry, oximetry and actigraphy for ambulatory recording of sleep apnea. Physiol Meas (2004) 1.22
Moving from the Oslerian paradigm to the post-genomic era: are asthma and COPD outdated terms? Thorax (2013) 1.20
Microbial DNA induces a host defense reaction of human respiratory epithelial cells. J Immunol (2004) 1.18
Inhibition of cAMP degradation improves regulatory T cell-mediated suppression. J Immunol (2009) 1.13
The anti-microbial peptide LL-37 inhibits the activation of dendritic cells by TLR ligands. Int Immunol (2006) 1.13
IL-22 is produced by innate lymphoid cells and limits inflammation in allergic airway disease. PLoS One (2011) 1.13
The antimicrobial peptide LL-37 modulates the inflammatory and host defense response of human neutrophils. Eur J Immunol (2010) 1.12
MDCT assessment of airway wall thickness in COPD patients using a new method: correlations with pulmonary function tests. Eur Radiol (2008) 1.11
The use of omalizumab in the treatment of severe allergic asthma: A clinical experience update. Respir Med (2009) 1.11
Sputum biomarker profiles in cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) and association between pulmonary function. Cytokine (2010) 1.09
Seasonal distribution of COPD exacerbations in the Prevention of Exacerbations with Tiotropium in COPD trial. Chest (2013) 1.09
Characterization of c-kit expression in small cell lung cancer: prognostic and therapeutic implications. Clin Cancer Res (2003) 1.09
Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study. Cancer Immunol Immunother (2007) 1.08
Onset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPD. COPD (2010) 1.06
Efficacy of a fixed combination of ciclesonide and formoterol: the EXCITED-study. Respir Med (2011) 1.03
Long-term repeatability of induced sputum cells and inflammatory markers in stable, moderately severe COPD. Chest (2003) 1.03
Soluble triggering receptor expressed on myeloid cells 1 is released in patients with stable chronic obstructive pulmonary disease. Clin Dev Immunol (2007) 1.02
Chronic obstructive pulmonary disease and premature aging. Am J Respir Crit Care Med (2007) 1.02
Dynamics of heart rate and sleep stages in normals and patients with sleep apnea. Neuropsychopharmacology (2003) 1.02
Bimosiamose, an inhaled small-molecule pan-selectin antagonist, attenuates late asthmatic reactions following allergen challenge in mild asthmatics: a randomized, double-blind, placebo-controlled clinical cross-over-trial. Pulm Pharmacol Ther (2005) 1.01
The prognostic impact of blood group-related antigen Lewis Y and the ABH blood groups in resected non-small cell lung cancer. Tumour Biol (2008) 1.00
Exposure of differentiated airway epithelial cells to volatile smoke in vitro. Respiration (2004) 1.00
Nonrandom variability of respiration during sleep in healthy humans. Sleep (2005) 1.00
Clinical application of a simple questionnaire for the differentiation of asthma and chronic obstructive pulmonary disease. Respir Med (2004) 0.99
Against all odds: anti-IgE for intrinsic asthma? Thorax (2013) 0.95
Comparison of exhaled breath condensate pH using two commercially available devices in healthy controls, asthma and COPD patients. Respir Res (2009) 0.94
Whole-body vibration therapy in intensive care patients: A feasibility and safety study. J Rehabil Med (2016) 0.94
Characterization of the interstitial lung and peripheral blood T cell receptor repertoire in cigarette smokers. Am J Respir Cell Mol Biol (2004) 0.93
Opportunities and challenges in the genetics of COPD 2010: an International COPD Genetics Conference report. COPD (2011) 0.93
Identification of individuals with alpha-1-antitrypsin deficiency by a targeted screening program. Respir Med (2007) 0.93
TLR3 but not TLR7/8 ligand induces allergic sensitization to inhaled allergen. J Immunol (2012) 0.92
Overall asthma control achieved with budesonide/formoterol maintenance and reliever therapy for patients on different treatment steps. Respir Res (2011) 0.91
Efficacy of Tiotropium + Olodaterol in Patients with Chronic Obstructive Pulmonary Disease by Initial Disease Severity and Treatment Intensity: A Post Hoc Analysis. Adv Ther (2015) 0.91
Indacaterol improves lung hyperinflation and physical activity in patients with moderate chronic obstructive pulmonary disease--a randomized, multicenter, double-blind, placebo-controlled study. BMC Pulm Med (2014) 0.91
Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD. A double-blind, randomised, non-inferiority, parallel-group, multicentre study. Respir Res (2009) 0.91
Severe and uncontrolled adult asthma is associated with vitamin D insufficiency and deficiency. Respir Res (2013) 0.89
Omalizumab and the risk of malignancy: results from a pooled analysis. J Allergy Clin Immunol (2012) 0.89
Acute and chronic effects of smoking on inflammation markers in exhaled breath condensate in current smokers. Respiration (2009) 0.88
Alpha-1 antitrypsin is elevated in exhaled breath condensate and serum in exacerbated COPD patients. Respir Med (2011) 0.88
c-kit expression in adenocarcinomas of the lung. Tumour Biol (2005) 0.87
An open-label, prospective phase I/II study evaluating the immunogenicity and safety of a ras peptide vaccine plus GM-CSF in patients with non-small cell lung cancer. Lung Cancer (2007) 0.87
Inhibition of NF-kappaB mediated inflammation by siRNA expressed by recombinant adeno-associated virus. J Virol Methods (2004) 0.86
Efficacy of indacaterol in the treatment of patients with COPD. Prim Care Respir J (2011) 0.86
Mast cells induce migration of dendritic cells in a murine model of acute allergic airway disease. Int Arch Allergy Immunol (2009) 0.86
Pulmonary dysfunction in non-cirrhotic patients with chronic viral hepatitis. Eur J Intern Med (2002) 0.86
Increased glutathione disulfide and nitrosothiols in sputum supernatant of patients with stable COPD. Chest (2004) 0.86
Discrimination between COPD patients with and without alpha 1-antitrypsin deficiency using an electronic nose. Respirology (2011) 0.85
Augmentation therapy for alpha-1 antitrypsin deficiency: towards a personalised approach. Orphanet J Rare Dis (2013) 0.85
Alpha1-antitrypsin deficiency - diagnostic testing and disease awareness in Germany and Italy. Respir Med (2013) 0.85
Ambient temperature impacts on pH of exhaled breath condensate. Respirology (2009) 0.84
Study design considerations in a large COPD trial comparing effects of tiotropium with salmeterol on exacerbations. Int J Chron Obstruct Pulmon Dis (2009) 0.84
Neutrophilic inflammation in induced sputum of patients with idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis (2003) 0.84
Benefits of whole body vibration training in patients hospitalised for COPD exacerbations - a randomized clinical trial. BMC Pulm Med (2014) 0.83
Synthesis and preliminary evaluation of (R,R)(S,S) 5-(2-(2-[4-(2-[(18)F]fluoroethoxy)phenyl]-1-methylethylamino)-1-hydroxyethyl)-benzene-1,3-diol ([(18)F]FEFE) for the in vivo visualisation and quantification of the beta2-adrenergic receptor status in lung. Bioorg Med Chem Lett (2003) 0.82
Anticholinergics in the treatment of chronic obstructive pulmonary disease. Respiration (2002) 0.82
Improvement in quality of life with omalizumab in patients with severe allergic asthma. Curr Med Res Opin (2006) 0.82
Impact of different definitions of airflow limitation on the prevalence of chronic obstructive pulmonary disease in the general population. Respiration (2010) 0.82
Imatinib-associated pulmonary alveolar proteinosis. Am J Med (2003) 0.82
The EvA study: aims and strategy. Eur Respir J (2012) 0.81
Cell-specific modulation of surfactant proteins by ambroxol treatment. Toxicol Appl Pharmacol (2005) 0.81
Lung transplantation: a treatment option in end-stage lung disease. Dtsch Arztebl Int (2014) 0.81
Fluticasone/formoterol combination therapy versus budesonide/formoterol for the treatment of asthma: a randomized, controlled, non-inferiority trial of efficacy and safety. J Asthma (2012) 0.81
SeroGRID: an improved method for the rapid selection of antigens with disease related immunogenicity. J Immunol Methods (2003) 0.81
[Evaluation of a modular out-patient education program for adult asthmatics with office-based specialists--results of a controlled, randomized multicenter trial]. Z Arztl Fortbild Qualitatssich (2006) 0.81
Krüppel-like zinc finger proteins in end-stage COPD lungs with and without severe alpha1-antitrypsin deficiency. Orphanet J Rare Dis (2012) 0.80
Efficacy and safety of indacaterol and tiotropium in COPD patients according to dyspnoea severity. Pulm Pharmacol Ther (2013) 0.80
Perspectives for improving the evaluation and access of therapies for rare lung diseases in Europe. Respir Med (2012) 0.80
Increased concentrations of glutathione in induced sputum of patients with mild or moderate allergic asthma. Ann Allergy Asthma Immunol (2004) 0.80
CD4-mediated regulatory T-cell activation inhibits the development of disease in a humanized mouse model of allergic airway disease. J Allergy Clin Immunol (2011) 0.80
TA-MUC1 epitope in non-small cell lung cancer. Lung Cancer (2008) 0.80
Prospective evaluation of current asthma control using ACQ and ACT compared with GINA criteria. Ann Allergy Asthma Immunol (2011) 0.79
Regulatory T cells more effectively suppress Th1-induced airway inflammation compared with Th2. J Immunol (2011) 0.79
Economic assessment of adjustable maintenance treatment with budesonide/formoterol in a single inhaler versus fixed treatment in asthma. Pharmacoeconomics (2005) 0.79
Tracheostomy and related host-pathogen interaction are associated with airway inflammation as characterized by tracheal aspirate analysis. Respir Med (2008) 0.79